Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Cancer Research UK Phase I Trial of AST-VAC2 (Allogeneic Dendritic Cell Vaccine) Administered Weekly Via Intradermal Injection in Patients With Non-small Cell Lung Cancer (NSCLC) in the Advanced and Adjuvant Settings

Trial Profile

A Cancer Research UK Phase I Trial of AST-VAC2 (Allogeneic Dendritic Cell Vaccine) Administered Weekly Via Intradermal Injection in Patients With Non-small Cell Lung Cancer (NSCLC) in the Advanced and Adjuvant Settings

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 May 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VAC 2 (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 07 May 2020 Results published in the Lineage Cell Therapeutics Media Release.
    • 07 May 2020 According to an Lineage Cell Therapeutics media release, the company will assume responsibility for further development of the VAC2 product candidate as well as future development opportunities derived from the VAC platform, while Cancer Research UK concludes the ongoing trial. This decision was based on an early review of the data collected by Cancer Research UK in the VAC2 trial under a clinical trial and option agreement.
    • 07 May 2020 According to an Lineage Cell Therapeutics media release, the company announced today that Cancer Research UK's Commercial Partnerships has permitted the company to conduct an early exercise of its option to acquire data from this ongoing study.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top